TELEHEALTH & PEPTIDE GROWTH
Build for
someone.
A bigger catalog won’t tell customers why to choose you. I write about finding your audience, making the offer matter, and building a growth plan around both.
I’m Shea Hoffman. I lead business development for telehealth and peptides at Lucyd. These are the questions I keep coming back to in conversations with founders.
The agency behind the thinking
My name is on the site.
Lucyd is behind the work.
I lead business development at Lucyd, a performance growth agency built for categories where platform policy, compliance, and unit economics shape the acquisition plan.
When there is a fit, the work moves into an operating team across paid media, creative, post-click conversion, and measurement. The goal is durable acquisition infrastructure, not a temporary traffic trick.
Featured essay
Should a cash-pay telehealth company hire an agency or build in-house?
A telehealth marketing agency can add range and speed. An internal team can own the learning. The right answer depends on what the business has already proved.
A point of view
A broad catalog is easy to assemble. A specific reason to choose your business takes more work.
The questions that interest me are practical: Who do you understand? What do they need? What can you credibly deliver? And how will you reach them without building the business around assumptions you haven’t tested?
Choose a starting point
Two difficult categories.
One operating discipline.
Cash-pay telehealth marketing
Audience, care model, acquisition economics, privacy-aware measurement, and the point at which a real operating team becomes useful.
Explore telehealth →02RUO peptide marketing
Positioning, operational trust, restricted-category acquisition, retention, and how to build something more durable than a hot catalog.
Explore peptides →More writing
Different questions.
The same discipline.
Peptide marketing
Peptide marketing agency or generalist? Compare the operating model
A peptide specialist is not automatically the better agency. Compare how each team handles positioning, constraints, continuity, conversion, and business economics.
Telehealth & product strategy
The next telehealth wedge may be the form factor
Strips, tablets, lozenges, pouches, gummies and sprays can create a reason to notice. The format still has to survive the clinical and commercial questions.
About Shea
The questions I bring to founder calls.
My experience spans advertising, sales, partnerships, and early-stage businesses. Today I lead business development at Lucyd, where I help determine whether there is a useful fit between a growth problem and a managed acquisition engagement.
I value clear thinking, direct communication, and systems that respect the customer. The goal is not activity for its own sake. It is a better signal, a more coherent path, and work that can hold up after the first result.
A useful next step
What are you trying to figure out?
If you’re building or expanding a telehealth or peptide business, we can talk through your audience, your acquisition plan, and whether Lucyd is the right partner for the next stage.
Schedule a conversation